Pfizer
Pfizer Inc. (NYSE: PFE) is a global biopharmaceutical company that discovers, develops, manufactures, markets, sells and distributes medicines and vaccines. Its products address areas including oncology, internal medicine, vaccines, inflammation and immunology, and rare diseases, serving patients and healthcare… From the company’s description.
In fiscal 2025, Pfizer reported revenue of $62.58B, down 1.6% from fiscal 2024, and net income of $7.79B. Its operating margin was 13.2%, and operations generated $11.70B in cash. Over the twelve months to Jun 28, 2026, revenue was $63.70B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pfizer does
In the company’s own words
Pfizer Inc. (NYSE: PFE) is a global biopharmaceutical company that discovers, develops, manufactures, markets, sells and distributes medicines and vaccines. Its products address areas including oncology, internal medicine, vaccines, inflammation and immunology, and rare diseases, serving patients and healthcare providers through commercial operations in developed and emerging markets. Pfizer also collaborates with other companies on product development and commercialization, including Comirnaty with BioNTech and Eliquis with Bristol Myers Squibb. The company has three operating segments—Biopharma, Pfizer CentreOne (PC1), a contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients, and Pfizer Ignite, which provides R&D services to selected biotechnology companies; Biopharma is its only reportable segment, and Pfizer is winding down Ignite. Biopharma’s portfolio includes brands such as Prevnar, Paxlovid, Eliquis, Ibrance and Vyndaqel. Pfizer reported total revenues of $62.6 billion for fiscal 2025. Its website is www.pfizer.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 78003
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pfizer — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Pfizer · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Pfizer’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Pfizer’s bonds, as funds hold them
Funds report holding 38 issues of Pfizer’s debt, $6.49B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.47%, maturing 2026 to 2065.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pfizer and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pfizer's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pfizer's last four quarterly filings that the numbers alone won't show?”